Consumer ADR: The Albanian experience in transposing EU Directive 2013/11

The Implications of the New Consumer Credit Directive for EU Credit Market Integration* POSITION PAPER

European consumer credit markets are still highly segmented: they differ in credit culture, composition and regulation. The new Consumer Credit Directive is intended to establish a maximal harmonization within member states to further increase integration. But is the Directive in its proposed version an adequate instrument to achieve this goal? To approach this question, the present position pa...

Urolithiasis in Children – Albanian Experience

Background: Urolithiasis is already one of the oldest diseases even in pediatric patients. The prevalence of kidney stones is estimated to be 1:20.000 children/year. The medium age of onset is between 5-7 years. The aim of our study was to see the characteristic features, predisposing factors and therapeutic procedures for urolithiasis in children, as well as metabolic abnormalities especially ...

The EU-ADR Web Platform: delivering advanced pharmacovigilance tools.

PURPOSE Pharmacovigilance methods have advanced greatly during the last decades, making post-market drug assessment an essential drug evaluation component. These methods mainly rely on the use of spontaneous reporting systems and health information databases to collect expertise from huge amounts of real-world reports. The EU-ADR Web Platform was built to further facilitate accessing, monitorin...

Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project

OBJECTIVE Data from electronic healthcare records (EHR) can be used to monitor drug safety, but in order to compare and pool data from different EHR databases, the extraction of potential adverse events must be harmonized. In this paper, we describe the procedure used for harmonizing the extraction from eight European EHR databases of five events of interest deemed to be important in pharmacovi...

Harmful impact of EU clinical trials directive.